178 related articles for article (PubMed ID: 36102635)
1. Ceftazidime-Avibactam plus Aztreonam for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria.
Sempere A; Viñado B; Los-Arcos I; Campany D; Larrosa N; Fernández-Hidalgo N; Rodríguez-Pardo D; González-López JJ; Nuvials X; Almirante B; Escolà-Vergé L
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0075122. PubMed ID: 36102635
[TBL] [Abstract][Full Text] [Related]
2. Activity of cefiderocol and synergy of novel β-lactam-β-lactamase inhibitor-based combinations against metallo-β-lactamase-producing gram-negative bacilli: insights from a two-year study (2019-2020).
Boattini M; Comini S; Bianco G; Iannaccone M; Casale R; Cavallo R; Costa C
J Chemother; 2023 May; 35(3):198-204. PubMed ID: 35731718
[TBL] [Abstract][Full Text] [Related]
3. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
Lee M; Abbey T; Biagi M; Wenzler E
Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
[TBL] [Abstract][Full Text] [Related]
4. Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Emeraud C; Escaut L; Boucly A; Fortineau N; Bonnin RA; Naas T; Dortet L
Antimicrob Agents Chemother; 2019 May; 63(5):. PubMed ID: 30858212
[TBL] [Abstract][Full Text] [Related]
5. Synergistic activity of ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-producing gram-negative pathogens.
Wenzler E; Deraedt MF; Harrington AT; Danizger LH
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):352-354. PubMed ID: 28602518
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales.
Falcone M; Daikos GL; Tiseo G; Bassoulis D; Giordano C; Galfo V; Leonildi A; Tagliaferri E; Barnini S; Sani S; Farcomeni A; Ghiadoni L; Menichetti F
Clin Infect Dis; 2021 Jun; 72(11):1871-1878. PubMed ID: 32427286
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Susceptibility Testing Methods for Aztreonam and Ceftazidime-Avibactam Combination Therapy on Extensively Drug-Resistant Gram-Negative Organisms.
Khan A; Erickson SG; Pettaway C; Arias CA; Miller WR; Bhatti MM
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0084621. PubMed ID: 34424044
[TBL] [Abstract][Full Text] [Related]
8. Occurrence of multi-carbapenemases producers among carbapenemase-producing Enterobacterales and in vitro activity of combinations including cefiderocol, ceftazidime-avibactam, meropenem-vaborbactam, and aztreonam in the COVID-19 era.
Bianco G; Boattini M; Comini S; Casale R; Iannaccone M; Cavallo R; Costa C
Eur J Clin Microbiol Infect Dis; 2022 Apr; 41(4):573-580. PubMed ID: 35061145
[TBL] [Abstract][Full Text] [Related]
9. Susceptibility testing for aztreonam plus ceftazidime/avibactam combination: A general guidance for clinical microbiology laboratories in India.
Bakthavatchalam YD; Walia K; Veeraraghavan B
Indian J Med Microbiol; 2022; 40(1):3-6. PubMed ID: 34949482
[TBL] [Abstract][Full Text] [Related]
10. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
[TBL] [Abstract][Full Text] [Related]
11. Management of serious infections caused by metallo β-lactamases with or without OXA-48-like expressing Enterobacterales with aztreonam and ceftazidime/avibactam combination: Dosing strategy for better clinical outcome.
Veeraraghavan B; Bakthavatchalam YD; Soman R; Swaminathan S; Manesh A; Nagvekar V; Nangia V
Indian J Med Microbiol; 2021 Jul; 39(3):286-288. PubMed ID: 33892973
[TBL] [Abstract][Full Text] [Related]
12. Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa.
Zhang Y; Zhao J; Han J; Fan Y; Xiong Z; Zou X; Li B; Liu X; Li Z; Lu B; Cao B
Microbiol Spectr; 2022 Apr; 10(2):e0274021. PubMed ID: 35315696
[TBL] [Abstract][Full Text] [Related]
13. Rapid characterization of carbapenem-resistant Enterobacterales by multiplex lateral flow assay and detection of ceftazidime-avibactam-aztreonam synergy.
Kalaivani R; Kali A; Surendran R; Sujaritha T; Ganesh Babu CP
Indian J Med Microbiol; 2024; 47():100530. PubMed ID: 38246242
[TBL] [Abstract][Full Text] [Related]
14. Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
Davido B; Fellous L; Lawrence C; Maxime V; Rottman M; Dinh A
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630191
[No Abstract] [Full Text] [Related]
15. Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity.
Smith NM; Boissonneault KR; Chen L; Petraitis V; Petraitiene R; Tao X; Zhou J; Lang Y; Kavaliauskas P; Bulman ZP; Holden PN; Cha R; Bulitta JB; Kreiswirth BN; Walsh TJ; Tsuji BT
Antimicrob Agents Chemother; 2022 Sep; 66(9):e0052722. PubMed ID: 35924913
[TBL] [Abstract][Full Text] [Related]
16. Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: Experience in a single center.
Zhen S; Lin Q; Chen Z; Shen Y; Chen X; Pang A; Yang D; Zhang R; Ma Q; He Y; Wei J; Zhai W; Jiang E; Han M; Wang J; Feng S
J Infect Chemother; 2024 Jul; 30(7):608-615. PubMed ID: 38215820
[TBL] [Abstract][Full Text] [Related]
17. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
[TBL] [Abstract][Full Text] [Related]
18. Combination of aztreonam, ceftazidime-avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis.
Mularoni A; Mezzatesta ML; Pilato M; Medaglia AA; Cervo A; Bongiorno D; Aprile A; Luca A; Stefani S; Grossi P
Int J Infect Dis; 2021 Jul; 108():510-512. PubMed ID: 34091004
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales.
Emilie CM; Alice CM; Marine G; Farfour E; Pourbaix A; Dortet L; Lucie L; Marc V
Eur J Clin Microbiol Infect Dis; 2024 Apr; 43(4):777-784. PubMed ID: 38277033
[TBL] [Abstract][Full Text] [Related]
20. Human simulated studies of aztreonam and aztreonam-avibactam to evaluate activity against challenging gram-negative organisms, including metallo-β-lactamase producers.
Crandon JL; Nicolau DP
Antimicrob Agents Chemother; 2013 Jul; 57(7):3299-306. PubMed ID: 23650162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
